source
- Avalyn plots $182M IPO; WHO prequalifies Novartis' malaria drugAvalyn Pharma plots $182M IPO: The biotech, which is making inhaled versions of approved pulmonary fibrosis medicines, anticipates about $182 million in net proceeds if it prices its initial public…Endpoints · 3mo ago↗ source
- Novartis pulls Pluvicto prostate cancer label expansion filing in the EUNovartis has withdrawn its EU application for Pluvicto's expansion into earlier prostate cancer treatment, despite US and UK approval for the same indication. The Swiss drugmaker failed to gain fav…Endpoints · 3mo ago↗ source
- Exclusive: UC Berkeley startup bets on jumping genes for GLP-1 gene therapyThe new generation of weight loss medicines does an unprecedented job of keeping off the pounds — if people stay on the drugs. Yet numerous studies suggest most of those who start taking GLP-1 drug…